LIFE News and Press, aTyr Pharma Inc. From 02/09/23

aTyr Pharma ( NASDAQ: LIFE ) shares fell over 7% premarket on Thursday after the biotherapeutics company priced its public offering of 22,225,000 shares at $2.25 per share. Underwriters have been granted a 30-day option to purchase up to an additional 3,333,750 shares at the p...

SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the pricing of its previously announced underwritten public ...

Summary aTyr Pharma is a biotherapeutics company focusing on tRNA synthetase research. The company's main product candidate is efzofitimod, a potential treatment for fibrotic lung diseases. In an early-stage study, efzofitimod appeared to show statistically nonsignificant positive t...

aTyr Pharma ( NASDAQ: LIFE ) is trading 10.5% lower after the bell after the company announced an underwritten public offering of its common stock. aTyr expects to grant the underwriters a 30-day option to purchase additional shares for an amount up to an additional 15% of th...

SAN DIEGO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has commenced an underwritten public offering of sha...

aTyr Pharma ( NASDAQ: LIFE ) shares rose ~5% on above-average volume on Monday after announcing that its partner Kyorin has started dosing in the pivotal Phase 3 study for lead asset efzofitimod in sarcoidosis, triggering a milestone payment worth $10M. aTyr ( LIFE ) has inked...

$10M milestone payment triggered by advancement of clinical program in Japan. Multiple centers in the U.S. and Japan are now open for enrollment. SAN DIEGO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the Company), a biotherapeutics company engaged in...

Symposia presentation to highlight significant advancements in understanding of efzofitimod’s MOA Poster presentation analyzing exposure-efficacy of efzofitimod further supports clinical proof-of-concept SAN DIEGO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ...

SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the European Patent Office (EPO) has provided a Notice ...

European Commission (EC) granted orphan drug designation to aTyr Pharma's ( NASDAQ: LIFE ) efzofitimod to treat sarcoidosis. Sarcoidosis is a disorder characterized by the growth of tiny collections of inflammatory cells (granulomas) in any body part, commonly the lungs and lymph ...